UCB : H2 2020 ahead of expectations, 2021 guidance clearly positive
>H2 ahead of expectations, UCB beats its 2020 targets - UCB has reported its results for 2020. If we focus on H2 we are clearly above market expectations. H2 revenues are 3.9% above consensus, recurring EBITDA is in line and core EPS is 20% above. Year-on-year revenue growth is still dynamic at 8% at constant currency (cc). The EBITDA margin contracted to 26.9 vs 29.1% a year earlier due to sustained growth in marketing costs (launches) and especially R&D (+24...UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.